European Psychiatry - Volume 33 - March 2016

681 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S677
4 Faculty of Pharmacy, University of Athens, Department of
Pharmacognosy and Natural Products Chemistry, Athens, Greece
5 GAIA Research Center, The Goulandris Natural History Museum,
Bioanalytical Department, Kifissia, Greece
∗ Corresponding author.
Alzheimer’s disease (AD), a neurodegenerative neuropsychiatric
disorder, is often comorbid with depression and anxiety. Neu-
ropsychiatric disorders are also characterized by sex differences.
However, most preclinical pharmacological studies are conducted
using only males. Herein, we used male and female twelve-month-
old mice (3xTg) expressing mutated forms of human proteins Tau,
APP and Presenilin1. These mice are considered a valid animal
model of AD. We investigated the effects of the natural compound
trans-crocin-4 (TC-4), which is derived from Crocus sativus and
the olive compound oleuropein on the cognitive, depressive and
anxious profile of 3xTg mice. We found that male and female
3xTg mice exhibited reduced locomotor activity and oleuropeine
treatment (100mg/kg i.p., for 21 days) did not reverse this pheno-
type. In addition, anxiety- and depressive-like behaviors were not
affected by genotype, sex or oleuropeine treatment. Interestingly,
oleuropeine exhibited a tendency to enhance cognitive perfor-
mance in male 3xTg mice. Treatment with TC-4 (50 and 150mg/kg,
i.p., acutely or chronically for 10 days) affected locomotor activ-
ity in a sex-differentiated manner. Interestingly, acute TC-4 clearly
enhanced cognitive performance in all groups although it reduced
center entries in the open field. Additionally, chronic TC-4 treat-
ment enhanced novel object discrimination mainly in male 3xTg
mice. Our findings highlight the potential of those natural com-
pounds, which warrant further investigation but also emphasize
the benefits of including both males and females in preclinical
pharmacological studies.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1026
A comparison of risperidone and
olanzapine in the acute treatment of
persistent delusional disorder: Data
from a retrospective chart review
K. Kulkarni ∗, R. Arasappa , K. Prasad , A. Zutshi , P. Chand ,
K. Muralidharan , P. Murthy
1 National Institute of Mental Health & Neurosciences, Psychiatry,
Bangalore, India
2 Epworth Hospital, Psychiatry, Melbourne, Australia
∗ Corresponding author.
Introduction There is a lack of pharmacological trials studying
drug response in Persistent Delusional Disorder (PDD) to guide clin-
ical practice. Available reviews of retrospective data indicate good
response to second-generation antipsychotics, but even such data
from India is sparse.
Objectives and aims We aimed to compare the response of acute
PDD to risperidone and olanzapine in our retrospective review.
Methods We conducted a retrospective chart review of patients
diagnosed with PDD (ICD-10) from 2000 to 2014 (n = 455) at our
Center. We selected the data of patients prescribed either olanzap-
ine or risperidone for the purpose of this extracteddata
about dose, drug compliance and response, adverse effects, number
of follow-up visits and hospitalizations. The study was approved by
the Institute Ethics Committee.
Results A total of 280/455 (61%) were prescribed risperidone and
86/455 (19%) olanzapine. The remaining (n = 89; 20%) had received
other antipsychotics. The two groups were comparable in socio-
demographic and clinical characteristics of PDD. Compliance was
good and comparable in both groups (> 80%, P = 0.2). Response to
treatment was comparable in both groups (85% partial response
and > 52% good response, all P > 0.3). Olanzapine was effective at
lower mean chlorpromazine equivalents than risperidone (240 vs.
391, P < 0.05).
Conclusion Our study indicates a good response to both risperi-
done and olanzapine, if compliance to treatment can be ensured.
In the absence of specific treatment guidelines for PDD, second-
generation antipsychotics like risperidone and olanzapine offer
good treatment options for this infrequently encountered and dif-
ficult to treat psychiatric disorder.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1027
Effects of typical and atypical
antipsychotics on spontaneous
neuronal network activity in vitro
C. Lange-Asschenfeldt∗, U. Henning , P. Görtz
Heinrich-Heine-University Duesseldorf, Psychiatry and
Psychotherapy, Duesseldorf, Germany
∗ Corresponding author.
Introduction Microelectrode arrays (MEAs) with cultured neu-
ronal networks are highly suitable to quantify neuroactive activity
and neurotoxicity of applied substances.
Objective Multiparametric characterization of functional alter-
ations of in vitro-neuronal network activity by different typical and
atypical antipsychotics.
Aims To identify differential effects of antipsychotics on sponta-
neous neuronal network activity as a functional readout.
Methods Cultured networks of dissociated cortical cells of post-
partal mice coupled to MEAs were exposed to increasing doses
of aripiprazole, clozapine, haloperidol, olanzapine, raclopride, and
risperidone.
Results We found a concentration-dependent inhibition of firing
patterns for all substances except olanzapine. All other substances
mediated a concomitant irreversible suppression of burst and spike
rates, a decrease of the burst duration and the number of spikes
in bursts as well as dose-dependent network desynchronization
(decrease of Cohen’s kappa). The comparison of the different
antipsychotics with regard to their half-maximal effective dose
values (EC-50) for inhibiting the spike rate yielded an increas-
ing order of EC50 values, i.e. a declining order of toxic potency,
of aripiprazole (8.77 M) < clozapine (9.36 M) < haloperidol
(9.77 M) < risperidone (15.9 M) < raclopride (22.7 M). No sig-
nificant correlations were identified between EC50 values of the
distinct antipsychotics and their binding affinity to the dopamine
D(2), the serotonin 5-HT(1A), 5-HT(2A), 5-HT(2C), and the M(1)
and M(2) muscarinic acetylcholine receptors.
Conclusion In MEAs, a dose-dependent neurotoxic effect of typ-
ical and atypical antipsychotics alike occurred at supratherapeutic
doses via a yet unknown mechanism that did not involve actions
on major receptor targets of these compounds.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1028
Increased libido as a buproion-SR side
effect: Clinical description of a case
L. Gallardo Borge∗, C. Noval Canga , L. Rodíguez Andrés ,
I. Sevillano Benito , M. Hernández García , A. Álvarez Astorga ,
R. Hernández Antón , S. Gómez Sánchez , G. Isidro García ,
P. Marqués Cabezas
Hospital Clínico Universitario, Servicio de Psiquiatría, Valladolid,
Spain
∗ Corresponding author.